奈达铂联合化疗在晚期妇科恶性肿瘤中的临床疗效对比研究

孙欣欣; 黄冬梅

doi:10.3969/j.issn.1000-8179.2012.11.012

奈达铂联合化疗在晚期妇科恶性肿瘤中的临床疗效对比研究

doi: 10.3969/j.issn.1000-8179.2012.11.012

孙欣欣,
黄冬梅^,

郑州大学第二附属医院妇产科（郑州市450014）

详细信息

通讯作者:
黄冬梅 hdm@zzu.edu.cn

计量
- 文章访问数: 18
- HTML全文浏览量: 2
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2011-11-02
- 修回日期: 2012-05-08

Efficacy of Taxane-related Chemotherapy with Nedaplatin and Other Platinum-based Drug Regimens in Patients with Advanced Gynecological Neoplasms

Xinxin SUN,
Dongmei HUANG^,

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China

More Information

Corresponding author: Dongmei HUANG; E-mail: hdm@zzu.edu.cn

摘要

摘要: 目的通过奈达铂/紫杉烷与奥沙利铂/紫杉烷、卡铂/紫杉烷联合化疗方案对比, 了解奈达铂/紫杉烷在晚期妇科恶性肿瘤化疗中的近期疗效和毒副反应。方法 2009年1月至201年6月郑州大学第二附属医院妇产科收治晚期妇科恶性肿瘤患者1 37例, 分为3组化疗方案治疗组, 回顾性对比分析各组化疗方案的近期疗效和毒副反应。结果奈达铂组、奥沙利铂组、卡铂组的总有效率分别为81.82%、80.43%、76.60%, 奈达铂组有效率与奥沙利铂组和卡铂组的比较差异均无统计学意义(P > 0.05)。奈达铂组血红蛋白降低发生率低于奥沙利铂组, 差异无统计学意义(P > 0.05), 白细胞降低、中性粒细胞降低及肝功能损伤的发生率低于奥沙利铂组, 差异有统计学意义(P < 0.05)。奈达铂组胃肠道反应发生率低于奥沙利铂组, 差异无统计学意义(P > 0.05)。奈达铂组血小板降低的发生率高于卡铂组(42.03% vs. 37.42%), 差异无统计学意义(P > 0.05)。奈达铂组Ⅲ~Ⅳ度骨髓抑制发生率49.2%, 与卡铂组相比差异无统计学意义(P > 0.05)奈达铂组未见过敏反应、肾功能损伤, 少部分神经感觉异常。结论奈达铂为新一代有效的广谱抗肿瘤药物, 其联合化疗的近期疗效与奥沙利铂、卡铂比较差异无统计学意义, 毒副反应以骨髓抑制和胃肠道反应为主, 与奥沙利铂、卡铂的比较无明显差异, 临床可根据患者的具体情况进行选择。
- 妇科肿瘤 /
- 奈达铂 /
- 奥沙利铂 /
- 卡铂 /
- 毒副反应
Abstract: Objective To determine the near-term therapeutic efficacy and toxicity of a nedaplatin/taxane regimen in patients with advanced gynecological neoplasms by comparing this regimen with oxaliplatin/taxane and carboplatin/taxane combination chemotherapy. Methods From January 2009 to June 2011, chemotherapy regimens containing nedaplatin/taxane(Group 1), oxaliplatin/taxane (Group 2), or carboplatin/ taxane(Group 3) was given to 137 patients with advanced gynecological neoplasms.A retrospective comparative study of the curative effect and toxicity of the chemotherapies was conducted in the three treatment groups. Results The effective response rates were 81.82%, 80.43%, and 76.60%in Groups 1, 2, and 3, respectively.However, there was no statistically significant difference among the three groups.Both gastrointestinal toxicity and hepatic toxicity were lower in Group 1 than in Group 2, but the difference was not statistically significant(P > 0.05).The incidence of neutropenia was significantly lower in Group 1 than in Group 2(P = 0.01).The incidence of thrombopenia was higher in Group 1 than in Group 3(42.03%and 37.42%, respectively), but the difference was not statistically significant(P > 0.05).Symptoms of anaphylaxis and nephrotoxicity were not observed in Group 1, although mild neurotoxicity was observed in a few patients. Conclusion There was no statistically significant difference between the curative effects of the combined chemotherapy regimen of the new-generation anticancer drugs oxaliplatin and carboplatin.The main toxicity of nedaplatin was myelosuppression and gastrointestinal toxicity.There was no significant difference among the toxicities of the combined chemotherapy of nedaplatin, oxaliplatin, and carboplatin.Thus, any of these drugs can be used to treat advanced gynecological neoplasms based on the specific clinical conditions of patients.
- Gynecological neoplasm /
- Nedaplatin /
- Oxaliplatin /
- Carboplatin /
- Toxicity

HTML全文

表 1 137例晚期或复发性妇科恶性肿瘤患者一般资料例

Table 1. Clinical data of 137 patients with advanced or relapsed malignant gynecological tumors

表 2 各组患者毒副反应比较例

Table 2. Comparison of the toxicities among the three treatment groups

参考文献(14)

[1]	叶瑞萍, 杨扬, 陈振东. 铂类抗肿瘤药物研究进展[J]. 国际肿瘤学杂志, 2008, 35(9): 674-677. doi: 10.3760/cma.j.issn.1673-422X.2008.09.010
[2]	王美清. 紫杉醇的临床毒副作用分析及对策[J]. 中国热带医学. 2007.7(2): 237-239. https://www.cnki.com.cn/Article/CJFDTOTAL-RDYX202012028.htm
[3]	李蕊, 令狐华. 上皮性卵巢癌的治疗进展[J]. 国际妇产科学杂志. 2010, 37(4): 277-280. https://www.cnki.com.cn/Article/CJFDTOTAL-GWVC202006025.htm
[4]	van Wijk FH, Lhomme C, Bolis G, et al. PhaseⅡstudy of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trialof the EORTC Gynaecological Cancer Group[J]. Eur J Cancer, 2003, 39: 78-85. doi: 10.1016/S0959-8049(02)00504-X
[5]	Mori T, Hosokawa K, Kinoshita Y, et al. Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma[J]. Int J Gynecol Cancer, 2008, 18(1): 85-89. doi: 10.1111/j.1525-1438.2007.00963.x
[6]	韩蕾, 卢冰, 欧阳伟炜, 等. 奈达铂或卡铂联合紫杉类药物同期放化治疗Ⅳ期NSCLC的临床随机对照研究[J]. 肿瘤预防与治疗, 2010, 23(05): 371-374. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZF201005005.htm
[7]	Barton MK. Oxaliplatin in the adjuvant treatment of colon cancer[J]. CA Cancer J Clin, 2012, 62(1): 3-4. doi: 10.3322/caac.21131
[8]	Alberto ME, Butera V, Russo N. Which one among the Pt-containing anticancer drugs more easily forms monoadducts with G and A DNA bases? A comparative study among oxaliplatin, nedaplatin. and carboplatin[J]. Inorg Chem, 2011, 50(15): 6965-6971. doi: 10.1021/ic200148n
[9]	Aitini E, Rossi A, Morselli P, et al. Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvanttreatment of colon cancer[J]. Cancer Manag Res, 2012, 4: 99-103.
[10]	鲁云, 张伟京. 奈达铂治疗恶性肿瘤研究进展[J]. 中国医院用药评价与分析, 2012, 12(1): 93-96. https://www.cnki.com.cn/Article/CJFDTOTAL-YYPF201201036.htm
[11]	王新林, 王湘辉. 多西紫杉醇联合奥沙利铂治疗复发性卵巢癌[J]. 中国医药指南, 2011, 9(32): 335-337. doi: 10.3969/j.issn.1671-8194.2011.32.262
[12]	Goto T, Takano M, Ohishi R, et al. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractoryepithelial ovarian, tubal and peritoneal cancers[J]. J Obstet Gynaecol Res, 2010, 36(4): 764-768. doi: 10.1111/j.1447-0756.2010.01217.x
[13]	夏修远, 房文铮, 宋洪涛. 重组人粒细胞集落刺激因子预防肿瘤化疗后骨髓抑制的疗效分析[J]. 中南药学, 2012, 10(3): 229-232. doi: 10.3969/j.issn.1672-2981.2012.03.020
[14]	李云芳. 紫杉醇联合顺铂治疗卵巢癌52例毒副作用及应对措施[J]. 齐鲁护理杂志, 2007, 13(23): 30-31. doi: 10.3969/j.issn.1006-7256.2007.23.017